The 68 never approached are almost certainly the 68 who had already left the trial by year 2 (inferred), and the published flow arithmetic is consistent with it
Numbers-honesty brief for an investing calibration. Nothing here is medical advice or a clinical recommendation.
The question
Verbatim: "In the Virta DRCP extension, why were 68 of 262 CCI participants never approached for the extension? If they were disproportionately non-responders, the 262-anchored 9.2% is closer to truth than the paper's 169-anchored 14.2%."
CCI = Continuous Care Intervention, the Virta / Indiana-and-Franciscan-Health trial arm. DRCP = the three-year diabetes-reversal continuation (extension) phase reported in the 2024 five-year paper. ITT = intention-to-treat. This is follow-up #2 from [[2026-07-30-virta-drcp-5yr-itt-remission-rate]], which named it "the single biggest remaining uncertainty in the calibration."
What we already know (from the vault)
- [[2026-07-30-virta-drcp-5yr-itt-remission-rate]] read the 2024 extension paper's full text directly and established the published anchors: 24 remitters at five years = 20% of 120 completers-with-data, 14.2% of the 169 extension consenters (the paper's ITT worst-observation-carried-forward denominator), 9.2% of the 262 originally enrolled. It quoted the one sentence the paper gives on approach: "After 2 years, 194 of the 262 CCI participants were approached for a three-year extension. Of these, 169 consented, and 122 remained in the study for five years." It recorded that the paper never says why 68 were not approached.
- That brief also recorded the one selection signal the 2024 paper does print: consenters versus decliners did not differ at baseline or at two years "except those who consented had significantly greater BHB concentration and lower fasting insulin level at two years" - mild enrichment for adherent responders.
- [[2026-05-25-virta-health-5yr-cohort-reversal-durability]] is the grandparent brief and the origin of the ~47% retention and ~10% derived-ITT figures.
- [[2026-05-21-lilly-glp1-longevity-thesis]] is the live position. The bear vector under test is behavioral reversal durably substituting for GLP-1 receptor agonists and eroding Eli Lilly recurring revenue.
- [[2026-05-24-virta-health-payer-contracts-lly-thesis-input]] and [[2026-07-18-capital-rx-reverse-lilly-relationship]] already resolved the adjacent payer question toward complement-with-soft-substitution.
What the web says
Three new primary sources were pulled in this run. The 2024 extension paper itself was not re-fetched (its prose is already on the record from the parent brief's direct read) and its publisher page is now behind a hard automation block; see Sources.
- The registry cannot settle this, and never will. ClinicalTrials.gov NCT02519309, pulled via API v2 on 2026-10-11 (record version date 2026-10-09):
hasResults: false. There is no Results module, no Participant Flow table, and nodocumentSectionat all, meaning no protocol, amendment, or statistical-analysis-plan PDF was ever uploaded. Last update posted 2022-04-27, two and a half years before the 2024 paper. Enrollment 465 ACTUAL, overall status COMPLETED, start 2015-08, primary completion 2018-04, completion 2021-04. - The registry does pre-specify the five-year endpoints, which makes the missing flow table a real omission rather than an out-of-scope one. Secondary outcomes include "Change from Baseline Type-2 Diabetes Status," "Change from Baseline Metabolic Syndrome Status," and "Change from Baseline Body Weight," each with time frame "42 and 60 Months (intervention arms only)." The detailed description likewise commits to "evaluate the sustainability of health outcomes achieved and the economic impact of therapeutic effects over 5 years."
- No posting obligation, which explains the absence without excusing it. The record carries
isFdaRegulatedDrug: falseandisFdaRegulatedDevice: false, so the trial is not an FDAAA "applicable clinical trial" and results posting is voluntary. A sponsor search of ClinicalTrials.gov returns five Virta Health records; only NCT05516797 (IGNITE) has results posted. There is no separate registry entry for the DRCP extension - the extension rides on NCT02519309. - The 2-year paper accounts for exactly 194 and exactly 68. Athinarayanan et al., Front Endocrinol 2019;10:348 (open access, read in full via Europe PMC), Results, verbatim: "One hundred ninety four participants (74% of 262) remained enrolled in the CCI at 2 years (Figure 1)." Its Table 1 is explicitly structured as three columns - "All" n = 262, "Completers with data" n = 194, "Dropout or missing data" n = 68. The 194 approached for the extension and the 68 never approached are numerically identical to the 2-year retained and 2-year lost groups.
- A sibling paper from the same registry states the invitation rule in words. Zoller et al., "Five-Year outcomes of a digitally delivered carbohydrate-reduced nutrition intervention for prediabetes," Front Nutr 2026;13:1839029 (PMC13329102, published 2026-06-19, read in full), Methods, verbatim: "We invited the 72 of 96 (75%) participants who completed the initial two-year study to enroll in a three-year extension (Figure 1)." Its flow figure: 96 enrolled, 72 active at 2 years (19 dropped year 1, 5 year 2), 58 consented, 14 declined, 50 at 3.5 years, 45 at 5 years. Same registry and same Franciscan Health Lafayette institutional review board. The extension protocol itself is not published and is not in the registry, so a shared invitation rule across the two arms is assumed, not sourced. In the prediabetes arm, 100% of the never-approached group is prior dropouts, by stated rule.
- The year-1 step is also published, so the departure timing of the 68 is partly known. Hallberg et al., Diabetes Ther 2018;9(2):583-612 (open access, read in full): "349 adults with T2D enrolled: CCI: n = 262 ... 218 participants (83%) remained enrolled in the CCI at 1 year," with the same three-column Table 1 structure: All 262 / Completers with data 218 / Dropout or missing data 44. So 44 of the 68 (65%) were gone inside year one; the remaining 24 left during year two.
- The 2-year paper gives the only zero-credit 262-anchored remission figure located in this cohort's literature. Verbatim: "The percentage of all CCI enrollees (N = 262) with verified reversal and remission requiring both completion of 2 years of the trial and an obtained laboratory value for HbA1c were 37.8 and 14.9%, respectively." That is precisely the zero-credit-to-dropouts construction the question is asking about, published by the same authors at the two-year mark and then not repeated at five years.
- Reasons for dropout are stated qualitatively and never counted. 2-year paper, verbatim: "CCI-participant-reported reasons for dropout included: intervening life events (e.g., family emergencies), difficulty attending or completing laboratory and clinic visits associated with the trial, and insufficient motivation for participation in the intervention." No breakdown by reason, no counts, no proportions. This is the single most load-bearing unquantified item. [inferred] Only the second reason (trial lab and clinic visit burden) is cleanly a trial-administration artifact; intervening life events occur in commercial deployments too, and insufficient motivation is the non-response signal.
- One search found no secondary source that explains the 68. A single WebSearch across press, trade, and aggregator coverage of the five-year study surfaced no source that reproduces the 194 figure, the flow diagram, or any participant accounting for the extension. The 122-of-262 completer count is the only cross-cohort number the secondary surface carries.
The reconciliation: 262 to 169 to 24, line by line
Every line is marked [sourced] with its source, or [inferred], or [unaccounted]. No line is estimated.
- 262 enrolled in the CCI arm (349 total T2D enrollees: 262 CCI, 87 usual care). [sourced: Hallberg 2018, Results]
- Minus 44 lost in year one, leaving 218 enrolled at 1 year (83% of 262). [sourced: Hallberg 2018, Results + Table 1 columns 262 / 218 / 44]
- Minus 24 more lost in year two, leaving 194 enrolled at 2 years (74% of 262); cumulative "dropout or missing data" = 68. [sourced: Athinarayanan 2019, Results + Table 1 columns 262 / 194 / 68]
- 194 approached for the three-year extension. [sourced: McKenzie 2024, Methods]
- The 68 never approached are the same 68 who were no longer retained at 2 years. [inferred, high confidence] Basis: exact numeric identity of the 194/68 split across the two papers, plus the explicitly stated invitation rule in the prediabetes arm of the same registry and extension ("We invited the 72 of 96 (75%) participants who completed the initial two-year study," Zoller 2026). Not printed as a statement in McKenzie 2024.
- Minus 25 who declined the extension, leaving 169 consenters = the published ITT worst-observation-carried-forward denominator. [sourced: McKenzie 2024, Methods; the 25 is 194 - 169, own subtraction]
- Minus 47 who dropped out before 5 years, minus 2 with missing 5-year HbA1c, leaving 120 with 5-year data; 122 "remained in the study." [sourced: McKenzie 2024, Methods + Table 1 footnote]
- 24 met the 2021 international consensus remission definition at 5 years. [sourced: McKenzie 2024, Results + Table 1]
Consistency check (own arithmetic): 68 + 25 + 47 + 2 + 120 = 262, with no residual. Note what this does and does not prove. It is an accounting identity almost everywhere: 25 is defined as 194 - 169, and 120 is 169 - 47 - 2 from the same footnote. The one genuinely independent cross-paper check is 262 - 194 = 68, matching the 2-year paper's own dropout column. Matching counts are consistent with the groups being the same people; they do not demonstrate it.
What remains unaccounted, precisely:
- [unaccounted] The composition of the 68 by reason. The three reported dropout reasons are never counted. One of them (trial lab and clinic visit burden) is specific to running a trial; one (intervening life events) occurs in any setting; one (insufficient motivation) is the non-response signal. Without counts, the split between "administrative" and "non-responder" inside the 68 is unknown.
- [unaccounted] The dropout-versus-missing-data split inside the 68. Both papers label that column "Dropout or missing data," and the Table 1 footnote conditions completer status on completing "laboratory, body composition assessments and clinic visits within the specified time-frame." If any of the 68 were still enrolled but merely missed a visit window, they would be administratively excluded from the approach list despite being active participants. The 2-year retention sentence (194 "remained enrolled") and the Table 1 completer column (194) are the same number, which bounds this subgroup as small, but the papers never split it.
- [unaccounted] Any outcome data for the 68. Non-existent by construction. They are in the "dropout or missing data" column precisely because they have no 2-year measurement, so no observed response or non-response can be attributed to them by anyone, including the authors.
- [unaccounted] A Participant Flow table in the registry. Never posted; not legally required; cannot be obtained from public sources.
- [unaccounted, minor] Registry enrollment reconciliation. NCT02519309 reports 465 ACTUAL enrolled. The published arms sum to 445 (262 CCI T2D + 87 usual care + 96 prediabetes). The 20-participant gap is not explained in any source read here.
Convergences and contradictions
- Convergence on half the premise, and that is the finding. The question's premise has two branches, and they resolve differently. The program-exited branch is supported: the 68 were not sampled out by a separate administrative process applied to an active cohort, they are the cumulative two-year attrition of the trial, and [inferred] they were invited out by an eligibility rule that required still being in the study (that rule is printed only for the prediabetes arm, so applying it to the type 2 diabetes arm is a second inference on top of the identity inference). The non-responder branch is untestable: they have no outcome data at all, and their baseline differences are not statistically demonstrable. The parent brief's framing ("68 never approached, 25 declined, unaccounted for in the published ITT") is correct, and the "why" is now reconstructible from the cohort's own earlier papers even though the 2024 paper does not say it.
- Convergence on direction of selection, with the magnitude unresolved. Observable baseline differences between the 194 and the 68, from Athinarayanan 2019 Table 1: the 68 were younger (51.9 vs 54.4 years), had higher baseline HbA1c (7.9% vs 7.5%, difference -0.4 +/- 0.2 SE), longer time since diagnosis (9.25 vs 8.15 years), were slightly more likely to be on a non-metformin diabetes medication (60.3% vs 55.7%), and were less likely to meet reversal criteria at baseline (10.3% vs 12.9%). [inferred] Most of those point the same way, toward modestly worse prognosis; younger age is not obviously a worse-prognosis marker and is included only for completeness. The paper's own verdict is that none of it is significant - "There were no differences between completers and dropouts on baseline characteristics for either group" - which is defensible given its Bonferroni threshold of P < 0.0012 across 43 variables. So: directionally worse-prognosis, not statistically demonstrable.
- A contradiction inside the cohort's own analytic practice. At two years the authors published both a covariate-adjusted model estimate on all 262 (53.5% reversal, 17.6% remission, generalized estimating equations with multiple imputation) and a zero-credit verified figure on all 262 (37.8% reversal, 14.9% remission). At five years they published neither 262-anchored figure, switching the ITT denominator to the 169 consenters. The 2024 paper's discussion then compounds it by writing "Remission was observed in 20% of those enrolled at five years," which is 20% of 120 completers-with-data, not of anyone's enrollment. The denominator shrank from 262 to 169 to, rhetorically, 120, across one cohort's publication history.
- A source-metadata trap worth recording. Europe PMC reports the 2024 paper as
isOpenAccess: N,hasSuppl: N. Both Crossref and the Elsevier article metadata endpoint confirm it is in fact CC-BY 4.0 withopenaccessType: Full. Europe PMC's flags describe its own index, not the article's license, so itshasSuppl: Nis not evidence that the 2024 paper lacks supplementary materials. Whether that paper has a supplementary appendix or a CONSORT-style flow figure is therefore unverified in this run, not resolved negatively.
Synthesis for RDCO
The answer is reconstructed from primary sources rather than speculated, and it points the calibration the way the question suspected, but the load-bearing step is an inference and should be carried as one. [inferred, high confidence] The 68 were never approached because the extension's invitation rule required having completed the original two-year trial, and 68 of 262 had not: 44 left inside year one, 24 more during year two. That is sourced from the cohort's own 1-year and 2-year papers, whose Table 1 structures carry the identical 262 / 218 / 44 and 262 / 194 / 68 splits, and it is confirmed as a rule in words by the prediabetes arm of the same registry and the same extension, published June 2026: "We invited the 72 of 96 (75%) participants who completed the initial two-year study." Two things here are inference rather than quotation: the identity statement (that the 68 unapproached are the 68 two-year losses), and the transfer of the prediabetes arm's stated invitation rule to the type 2 diabetes arm. Both are tight but neither is printed: the counts match exactly, and the rule is stated only for the sibling arm.
So the 68 are not an administrative or random subsample. [inferred, following from the identity above] They are people for whom the program did not run to completion. That is not the same thing as biological non-response, and the brief should not pretend otherwise: the authors list trial-visit burden and intervening life events alongside insufficient motivation as dropout reasons, and never count them, so an unknown fraction of the 68 left for reasons unrelated to the treatment working. Of those three, only trial-visit burden is specific to running a trial. [inferred, not sourced] For the question the thesis actually asks - what does a payer observe across an unselected book of business - the distinction largely collapses, because a member who stops engaging delivers no remission regardless of why, and a commercial deployment substitutes its own frictions for the trial's rather than removing them. That step is reasoning, not evidence, and it is where a reader who disagrees should push. The 25 who declined the extension are a separate and milder case: they did complete two years, their baseline and two-year characteristics matched the consenters except for lower beta-hydroxybutyrate and higher fasting insulin at two years, and they are the group for which "mildly enriched against" is the honest description.
The verdict on the two anchors: prefer 9.2% for payer-facing, unselected-population comparisons, and use 14.2% only as a consent-conditioned durability figure, explicitly labelled as such. 14.2% is the remission rate conditional on having completed two years of the program and then consenting to three more. That is a legitimate figure for exactly one question - how durable is remission among people who opt into continuation - and it is the right figure to put beside other trials' randomized-population ITT rates only if those comparators are similarly consent-conditioned. Whether Look AHEAD and DiRECT (the comparators the 2024 paper's discussion cites) are ITT or completer-anchored is not established here and is already a separately queued question. One point in 14.2%'s favour that should not be lost: it is itself worst-observation-carried-forward, so it already gives zero credit to the 47 extension dropouts. It is not a completer rate. Its defect is the consent gate on its denominator, not its handling of missing data. 9.2% (24/262, own arithmetic) is the floor and the better payer-facing anchor, and it has a direct precedent in this cohort's own literature: the same authors published exactly that construction at two years ("the percentage of all CCI enrollees (N = 262) with verified ... remission ... was 14.9%"). For a defensible band rather than a point: at two years the gap between the authors' 262-anchored zero-credit figure (14.9%) and their 262-anchored model-based figure (17.6%) was +18% relative. Granting the same model generosity to the five-year number gives roughly 10.9%. So carry 9.2% as the anchor, ~10.9% as one illustrative upward scenario rather than a demonstrated ceiling, and 14.2% as a labelled consent-conditioned figure. Three caveats on the 10.9%, all of which cut against treating it as a bound: it is my own arithmetic; the 2-year side uses the looser 2009 partial-or-complete remission definition rather than the 2021 consensus definition used at five years; and it cannot be decomposed per participant, because the 2-year model estimates are covariate-adjusted marginals, not imputed counts. Most importantly, the unobserved share is roughly twice as large at five years (142 of 262, 54%) as at two years (68 of 262, 26%), so if an imputation gap scales with missingness the true adjustment would be larger than +18% relative, not smaller.
Two things this does not change, and one new datum it adds. It does not change the direction of the parent brief's verdict: behavioral remission at five years is a real minority outcome that decays inside a single cohort (24.3% to 14.2% ITT worst-observation-carried-forward, both on the 169 denominator, year two to year five, per [[2026-07-30-virta-drcp-5yr-itt-remission-rate]]), so it thins and delays prescriptions rather than replacing them, and the bear vector stays trimmed. It does not rescue the payer-savings arm, whose medication-reduction figures remain completer-only with no published ITT. What it adds is a reusable research gate: when a paper reports an extension-phase ITT, the extension's denominator is almost never the trial's enrollment, and the missing participants are usually recoverable from the predecessor paper's Table 1 rather than from the registry. In this case the registry was a dead end - no posted results, no flow table, no protocol document, no posting obligation - and the predecessor papers closed the arithmetic to the participant. Check the earlier paper's completer column before checking the registry.
Why this is in the vault
This resolves open follow-up #2 of [[2026-07-30-virta-drcp-5yr-itt-remission-rate]], pending only the supplementary-appendix check named below, and fixes which remission figure the behavioral-substitution bear vector in [[2026-05-21-lilly-glp1-longevity-thesis]] is weighted against: 9.2% on 262, not 14.2% on 169, with 14.2% retained only as a labeled consent-conditioned figure. It also supplies the auditable reconciliation (262 to 218 to 194 to 169 to 122 to 120 to 24) that any future challenge to the thesis's Virta input can be checked against without re-reading four papers.
Open follow-ups
- Does the 2024 extension paper have a supplementary appendix or a CONSORT-style participant-flow figure? Unverified here. Europe PMC's
hasSuppl: Ndescribes its own index, not the article, and the publisher page is behind a hard Cloudflare automation block. A single institutional-network or logged-in browser session would settle it, and it is the one remaining place a printed statement about the 68 could exist. Test-plan step, not a desk-research item. - Can the registry's 465 ACTUAL enrollment be reconciled against the 445 accounted for across the published arms (262 CCI T2D, 87 usual care, 96 prediabetes)? The 20-participant gap appeared in no source read here; the metabolic-syndrome-only subgroup named in the registry's brief summary is the obvious candidate and has no published paper located yet.
- Does the cohort's prediabetes five-year paper (Zoller 2026, Front Nutr) change the prevention-side input to the thesis? It is new (June 2026), open access, from the same registry and extension, and reports 22% regression to normoglycemia and 13% progression to type 2 diabetes at five years anchored on 58 extension consenters out of 96 originally enrolled. It has never been read into the vault and carries the same denominator question in a cleaner, fully-stated form.
- Test-plan step, not a queue item: a direct request to the authors for the dropout-reason counts inside the 68, and for the dropout-versus-missing-data split, is the only route to resolving the administrative-versus-non-responder share. No public source carries it.
Related
- [[2026-07-30-virta-drcp-5yr-itt-remission-rate]] - parent brief; this closes its open follow-up on the missing 93 (the 68 never approached plus the 25 who declined)
- [[2026-05-25-virta-health-5yr-cohort-reversal-durability]] - grandparent brief; origin of the ~47% retention and derived-ITT framing
- [[2026-05-21-lilly-glp1-longevity-thesis]] - the live position this calibrates
- [[2026-05-24-virta-health-payer-contracts-lly-thesis-input]] - payer-economics arm, whose inputs remain completer-only
- [[2026-07-18-capital-rx-reverse-lilly-relationship]] - substitution-versus-complement resolution on the payer side
- [[2026-07-18-virta-covered-lives-tracker-data-source]] - scale-side tracker for the same thesis
- [[2026-05-22-tim-ferriss-sami-inkinen-virta-t2d-rowing]] - Inkinen anchor interview
Sources
Primary, fetched and read in full this run:
- ClinicalTrials.gov NCT02519309, "Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake," Virta Health. Pulled via API v2: https://clinicaltrials.gov/api/v2/studies/NCT02519309?format=json (HTTP 200, 20,589 bytes, record version 2026-10-09).
hasResults: false; no Results or Participant Flow module; nodocumentSection; enrollment 465 ACTUAL; 42- and 60-month secondary outcomes pre-specified;isFdaRegulatedDrug: false. - Virta Health sponsor search: https://clinicaltrials.gov/api/v2/studies?query.spons=Virta+Health - five records; only NCT05516797 has posted results; no separate registration for the extension.
- Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, Volek JS, Phinney SD, McCarter JP. "Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial." Front Endocrinol 2019;10:348. PMID 31231311, PMC6561315. Full text via Europe PMC REST: https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6561315/fullTextXML - Results (retention, diabetes status), Table 1 (three-column 262 / 194 / 68), statistical-analysis section read directly.
- Hallberg SJ, McKenzie AL, Williams PT, et al. "Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year." Diabetes Ther 2018;9(2):583-612. PMID 29417495, PMC6104272. Full text via Europe PMC REST - Results and Table 1 (262 / 218 / 44) read directly.
- Zoller AR, Athinarayanan SJ, Van Tieghem MR, Adams RN, Roberts CGP, Volek JS, Phinney SD, McKenzie AL. "Five-Year outcomes of a digitally delivered carbohydrate-reduced nutrition intervention for prediabetes: durability of diabetes prevention." Front Nutr 2026;13:1839029. PMID 42404153, PMC13329102. Full text via Europe PMC REST - Methods (invitation rule), Figure 1 flow caption, Table 1 (consenters versus decliners) read directly.
- Crossref API, DOI 10.1016/j.diabres.2024.111898 - CC-BY 4.0 confirmed,
component-count: null. - Elsevier article metadata endpoint, PII S0168822724008088 -
openaccess: 1,openaccessType: Full,openaccessUserLicense: CC-BY 4.0. Full-text body not returned without an API key. - Unpaywall, same DOI -
is_oa: true, hybrid, CC-BY, publisher-hosted, no repository copy.
Primary, read in a prior run and relied on here without re-fetch:
- McKenzie AL, Athinarayanan SJ, Van Tieghem MR, Volk BM, Roberts CGP, Adams RN, Volek JS, Phinney SD, Hallberg SJ. "5-Year effects of a novel continuous remote care model with carbohydrate-restricted nutrition therapy including nutritional ketosis in type 2 diabetes: An extension study." Diabetes Res Clin Pract 2024;217:111898. DOI 10.1016/j.diabres.2024.111898. Methods, Results, Table 1 and footnote quoted from the direct full-text read recorded in [[2026-07-30-virta-drcp-5yr-itt-remission-rate]].
Unreachable this run, with exact failures:
- Publisher full text, https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00808-8/fulltext - HTTP 403 via curl with browser User-Agent; headless Playwright and headed Chrome-channel Playwright both held at the Cloudflare interstitial ("Just a moment...", body length 288) through 60 seconds of polling. Supplementary-materials listing therefore not enumerated.
- https://www.sciencedirect.com/science/article/pii/S0168822724008088 - HTTP 403 via curl with browser User-Agent.
- ClinicalTrials.gov record-version history, https://clinicaltrials.gov/api/int/studies/NCT02519309/history - HTTP 403, plain and with browser User-Agent.
- Elsevier text-and-data-mining full-text endpoint, https://api.elsevier.com/content/article/PII:S0168822724008088?httpAccept=text/xml - HTTP 429 on first attempt, then HTTP 200 returning
coredatametadata only (2,054 bytes, no article body) without an API key. - Europe PMC supplementary-files endpoint for PMC13329102 - returned a non-archive payload (159,744 bytes, "End-of-central-directory signature not found"); the prediabetes paper's supplementary tables were not opened.
Own arithmetic, labelled, not printed in any source:
- 24/262 = 9.2%; 194 - 169 = 25 decliners; 44 + 24 = 68 cumulative two-year loss, so 44/68 = 65% of the never-approached left inside year one; closure check 68 + 25 + 47 + 2 + 120 = 262; 14.9% x 262 = 39.0 verified two-year remitters; 17.6/14.9 = +18% relative model generosity at two years, applied to 9.2% gives ~10.9% as a labelled scenario.